Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa.
Identifieur interne : 000352 ( Main/Exploration ); précédent : 000351; suivant : 000353Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa.
Auteurs : Nelly Mugo [Kenya] ; Nana Akosua Ansah ; Deborah Marino ; Alfred Saah ; Elizabeth I O. GarnerSource :
- Human vaccines & immunotherapeutics [ 2164-554X ] ; 2015.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Anticorps antiviraux (sang), Effets secondaires indésirables des médicaments (anatomopathologie), Effets secondaires indésirables des médicaments (épidémiologie), Enfant, Femelle, Ghana, Humains, Infections à papillomavirus (), Jeune adulte, Kenya, Méthode en double aveugle, Placebo, Résultat thérapeutique, Sénégal, Vaccin recombinant quadrivalent contre les papillomavirus humains de type 6, 11, 16 et 18 (administration et posologie), Vaccin recombinant quadrivalent contre les papillomavirus humains de type 6, 11, 16 et 18 (effets indésirables), Vaccin recombinant quadrivalent contre les papillomavirus humains de type 6, 11, 16 et 18 (immunologie), Volontaires sains.
- MESH :
- administration et posologie : Vaccin recombinant quadrivalent contre les papillomavirus humains de type 6, 11, 16 et 18.
- anatomopathologie : Effets secondaires indésirables des médicaments.
- effets indésirables : Vaccin recombinant quadrivalent contre les papillomavirus humains de type 6, 11, 16 et 18.
- immunologie : Vaccin recombinant quadrivalent contre les papillomavirus humains de type 6, 11, 16 et 18.
- sang : Anticorps antiviraux.
- épidémiologie : Effets secondaires indésirables des médicaments.
- Adolescent, Adulte, Enfant, Femelle, Ghana, Humains, Infections à papillomavirus, Jeune adulte, Kenya, Méthode en double aveugle, Placebo, Résultat thérapeutique, Sénégal, Volontaires sains.
- Wicri :
English descriptors
- KwdEn :
- Adolescent, Adult, Antibodies, Viral (blood), Child, Double-Blind Method, Drug-Related Side Effects and Adverse Reactions (epidemiology), Drug-Related Side Effects and Adverse Reactions (pathology), Female, Ghana, Healthy Volunteers, Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (administration & dosage), Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (adverse effects), Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (immunology), Humans, Kenya, Papillomavirus Infections (prevention & control), Placebos, Senegal, Treatment Outcome, Young Adult.
- MESH :
- chemical , administration & dosage : Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18.
- chemical , adverse effects : Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18.
- chemical , blood : Antibodies, Viral.
- chemical , immunology : Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18.
- geographic : Ghana, Kenya, Placebos, Senegal.
- epidemiology : Drug-Related Side Effects and Adverse Reactions.
- pathology : Drug-Related Side Effects and Adverse Reactions.
- prevention & control : Papillomavirus Infections.
- Adolescent, Adult, Child, Double-Blind Method, Female, Healthy Volunteers, Humans, Treatment Outcome, Young Adult.
Abstract
Due to sporadic and not easily accessible cervical cancer screening, human papillomavirus (HPV)-related cervical cancer is a leading cause of cancer death in Sub-Saharan African women. This study was designed to assess the safety and immunogenicity of a quadrivalent human papillomavirus (qHPV) vaccine in sub-Saharan African women. This seven month, double-blind study enrolled 250 healthy, human immunodeficiency virus (HIV)-uninfected females ages 9-26 residing in Ghana, Kenya, and Senegal. Thirty females ages 13-15 and 120 females ages 16-26 received qHPV vaccine. In addition, 100 females ages 9-12 y were randomized in a 4:1 ratio to receive either qHPV vaccine (n = 80) or placebo (n = 20 ). The primary immunogenicity hypothesis was that an acceptable percentage of subjects who received the qHPV vaccine seroconvert to HPV6/11/16/18 at 4 weeks post-dose 3, defined as the lower bound of the corresponding 95% confidence interval (CI) exceeding 90%. The primary safety objective was to demonstrate that qHPV vaccine was generally well tolerated when administered in a 3-dose regimen. The pre-specified statistical criterion for the primary immunogenicity hypothesis was met: the lower bound of the 95% exact binomial CI on the seroconversion rate was at least 98% for each vaccine HPV type and all subjects seroconverted by 4 weeks post-dose 3. Across vaccination groups, the most common adverse events (AE) were at the injection site, including pain, swelling, and erythema. No subject discontinued study medication due to an AE and no serious AEs were reported. There were no deaths. This study demonstrated that qHPV vaccination of sub-Saharan African women was highly immunogenic and generally well tolerated.
DOI: 10.1080/21645515.2015.1008877
PubMed: 25912475
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000568
- to stream PubMed, to step Curation: 000568
- to stream PubMed, to step Checkpoint: 000568
- to stream Ncbi, to step Merge: 000811
- to stream Ncbi, to step Curation: 000811
- to stream Ncbi, to step Checkpoint: 000811
- to stream Main, to step Merge: 000352
- to stream Main, to step Curation: 000352
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa.</title><author><name sortKey="Mugo, Nelly" sort="Mugo, Nelly" uniqKey="Mugo N" first="Nelly" last="Mugo">Nelly Mugo</name><affiliation wicri:level="1"><nlm:affiliation>a Kenyatta National Hospital ; Nairobi , Kenya.</nlm:affiliation><country xml:lang="fr">Kenya</country><wicri:regionArea>a Kenyatta National Hospital ; Nairobi </wicri:regionArea></affiliation></author><author><name sortKey="Ansah, Nana Akosua" sort="Ansah, Nana Akosua" uniqKey="Ansah N" first="Nana Akosua" last="Ansah">Nana Akosua Ansah</name></author><author><name sortKey="Marino, Deborah" sort="Marino, Deborah" uniqKey="Marino D" first="Deborah" last="Marino">Deborah Marino</name></author><author><name sortKey="Saah, Alfred" sort="Saah, Alfred" uniqKey="Saah A" first="Alfred" last="Saah">Alfred Saah</name></author><author><name sortKey="Garner, Elizabeth I O" sort="Garner, Elizabeth I O" uniqKey="Garner E" first="Elizabeth I O" last="Garner">Elizabeth I O. Garner</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25912475</idno><idno type="pmid">25912475</idno><idno type="doi">10.1080/21645515.2015.1008877</idno><idno type="wicri:Area/PubMed/Corpus">000568</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000568</idno><idno type="wicri:Area/PubMed/Curation">000568</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000568</idno><idno type="wicri:Area/PubMed/Checkpoint">000568</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000568</idno><idno type="wicri:Area/Ncbi/Merge">000811</idno><idno type="wicri:Area/Ncbi/Curation">000811</idno><idno type="wicri:Area/Ncbi/Checkpoint">000811</idno><idno type="wicri:Area/Main/Merge">000352</idno><idno type="wicri:Area/Main/Curation">000352</idno><idno type="wicri:Area/Main/Exploration">000352</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa.</title><author><name sortKey="Mugo, Nelly" sort="Mugo, Nelly" uniqKey="Mugo N" first="Nelly" last="Mugo">Nelly Mugo</name><affiliation wicri:level="1"><nlm:affiliation>a Kenyatta National Hospital ; Nairobi , Kenya.</nlm:affiliation><country xml:lang="fr">Kenya</country><wicri:regionArea>a Kenyatta National Hospital ; Nairobi </wicri:regionArea></affiliation></author><author><name sortKey="Ansah, Nana Akosua" sort="Ansah, Nana Akosua" uniqKey="Ansah N" first="Nana Akosua" last="Ansah">Nana Akosua Ansah</name></author><author><name sortKey="Marino, Deborah" sort="Marino, Deborah" uniqKey="Marino D" first="Deborah" last="Marino">Deborah Marino</name></author><author><name sortKey="Saah, Alfred" sort="Saah, Alfred" uniqKey="Saah A" first="Alfred" last="Saah">Alfred Saah</name></author><author><name sortKey="Garner, Elizabeth I O" sort="Garner, Elizabeth I O" uniqKey="Garner E" first="Elizabeth I O" last="Garner">Elizabeth I O. Garner</name></author></analytic><series><title level="j">Human vaccines & immunotherapeutics</title><idno type="eISSN">2164-554X</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Antibodies, Viral (blood)</term><term>Child</term><term>Double-Blind Method</term><term>Drug-Related Side Effects and Adverse Reactions (epidemiology)</term><term>Drug-Related Side Effects and Adverse Reactions (pathology)</term><term>Female</term><term>Ghana</term><term>Healthy Volunteers</term><term>Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (administration & dosage)</term><term>Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (adverse effects)</term><term>Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (immunology)</term><term>Humans</term><term>Kenya</term><term>Papillomavirus Infections (prevention & control)</term><term>Placebos</term><term>Senegal</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Anticorps antiviraux (sang)</term><term>Effets secondaires indésirables des médicaments (anatomopathologie)</term><term>Effets secondaires indésirables des médicaments (épidémiologie)</term><term>Enfant</term><term>Femelle</term><term>Ghana</term><term>Humains</term><term>Infections à papillomavirus ()</term><term>Jeune adulte</term><term>Kenya</term><term>Méthode en double aveugle</term><term>Placebo</term><term>Résultat thérapeutique</term><term>Sénégal</term><term>Vaccin recombinant quadrivalent contre les papillomavirus humains de type 6, 11, 16 et 18 (administration et posologie)</term><term>Vaccin recombinant quadrivalent contre les papillomavirus humains de type 6, 11, 16 et 18 (effets indésirables)</term><term>Vaccin recombinant quadrivalent contre les papillomavirus humains de type 6, 11, 16 et 18 (immunologie)</term><term>Volontaires sains</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Ghana</term><term>Kenya</term><term>Placebos</term><term>Senegal</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccin recombinant quadrivalent contre les papillomavirus humains de type 6, 11, 16 et 18</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Effets secondaires indésirables des médicaments</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccin recombinant quadrivalent contre les papillomavirus humains de type 6, 11, 16 et 18</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Drug-Related Side Effects and Adverse Reactions</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Vaccin recombinant quadrivalent contre les papillomavirus humains de type 6, 11, 16 et 18</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Drug-Related Side Effects and Adverse Reactions</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Papillomavirus Infections</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Effets secondaires indésirables des médicaments</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Child</term><term>Double-Blind Method</term><term>Female</term><term>Healthy Volunteers</term><term>Humans</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Enfant</term><term>Femelle</term><term>Ghana</term><term>Humains</term><term>Infections à papillomavirus</term><term>Jeune adulte</term><term>Kenya</term><term>Méthode en double aveugle</term><term>Placebo</term><term>Résultat thérapeutique</term><term>Sénégal</term><term>Volontaires sains</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Ghana</term><term>Kenya</term><term>Sénégal</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Due to sporadic and not easily accessible cervical cancer screening, human papillomavirus (HPV)-related cervical cancer is a leading cause of cancer death in Sub-Saharan African women. This study was designed to assess the safety and immunogenicity of a quadrivalent human papillomavirus (qHPV) vaccine in sub-Saharan African women. This seven month, double-blind study enrolled 250 healthy, human immunodeficiency virus (HIV)-uninfected females ages 9-26 residing in Ghana, Kenya, and Senegal. Thirty females ages 13-15 and 120 females ages 16-26 received qHPV vaccine. In addition, 100 females ages 9-12 y were randomized in a 4:1 ratio to receive either qHPV vaccine (n = 80) or placebo (n = 20 ). The primary immunogenicity hypothesis was that an acceptable percentage of subjects who received the qHPV vaccine seroconvert to HPV6/11/16/18 at 4 weeks post-dose 3, defined as the lower bound of the corresponding 95% confidence interval (CI) exceeding 90%. The primary safety objective was to demonstrate that qHPV vaccine was generally well tolerated when administered in a 3-dose regimen. The pre-specified statistical criterion for the primary immunogenicity hypothesis was met: the lower bound of the 95% exact binomial CI on the seroconversion rate was at least 98% for each vaccine HPV type and all subjects seroconverted by 4 weeks post-dose 3. Across vaccination groups, the most common adverse events (AE) were at the injection site, including pain, swelling, and erythema. No subject discontinued study medication due to an AE and no serious AEs were reported. There were no deaths. This study demonstrated that qHPV vaccination of sub-Saharan African women was highly immunogenic and generally well tolerated.</div></front></TEI><affiliations><list><country><li>Kenya</li></country></list><tree><noCountry><name sortKey="Ansah, Nana Akosua" sort="Ansah, Nana Akosua" uniqKey="Ansah N" first="Nana Akosua" last="Ansah">Nana Akosua Ansah</name><name sortKey="Garner, Elizabeth I O" sort="Garner, Elizabeth I O" uniqKey="Garner E" first="Elizabeth I O" last="Garner">Elizabeth I O. Garner</name><name sortKey="Marino, Deborah" sort="Marino, Deborah" uniqKey="Marino D" first="Deborah" last="Marino">Deborah Marino</name><name sortKey="Saah, Alfred" sort="Saah, Alfred" uniqKey="Saah A" first="Alfred" last="Saah">Alfred Saah</name></noCountry><country name="Kenya"><noRegion><name sortKey="Mugo, Nelly" sort="Mugo, Nelly" uniqKey="Mugo N" first="Nelly" last="Mugo">Nelly Mugo</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000352 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000352 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:25912475
|texte= Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25912475" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SidaGhanaV1
| This area was generated with Dilib version V0.6.31. |  |